Deploying a 'Gold Standard' CSF Biomarker Panel For Use in Alzheimer's Disease Research

A multinational in vitro diagnostic company (IVD) had developed a multi-analyte cerebral spinal fluid diagnostic panel with utility in identifying patients with early indications of both mild cognitive impairment and full-blown Alzheimer's disease. The diagnostic company needed a CRO partner with deep experience in exploratory biomarker analysis in a regulated setting, a strong track record in central nervous system (CNS) trials and the global capability to deploy the diagnostic panel in multiple clinical programs.